Clinical trial NCT05922384: Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma
Official title: Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: HIV Infections
Lymphoma
Keywords: HIV-1 infection; Lymphoma; gene therapy; 7shRNA
Lead sponsor: Affiliated Hospital of Guangdong Medical University
Sponsor class: OTHER
First posted: 2023-06-28
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This pilot clinical trial studies gene therapy in treating patients with HIV-1 infecetion combined with lymphoma undergoing 7shRNA lentiviral vector transduced CD34+ hematopoietic stem cell transplant. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, CD34+hematopoietic stem cells are mobilized and collected from the patient's peripheral blood. The CD34+stem cells are then isolated and transduced with lenti-7shRNA vector and reinfused to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

Detailed description: Primary objectives:

1. To determine the safety and feasibility of using lenti-7shRNA transduced hematopoietic stem/progenitor cells in the setting of autologous hematopoietic cell transplantation for treatment of HIV infection combined with lymphoma. The safety of the genetically modified product used in the transplant procedure will be assessed by monitoring each subject for adverse events (procedure related toxicity); absolute neutrophil count (ANC)/platelet engraftment (sustained recovery); and evidence of replication competent vector or vector recombination with the human immunodeficiency virus (HIV) quasi-species present in the patient.
2. To determine the quantity and duration of vector-marked peripheral blood cells and to characterize: the duration and level of gene marking and expression of the anti-HIV shRNA in these transduced cells, and the characterization of the integration sites of vector sequences in circulating cells if there is a clinical syndrome suggestive of a clonal expansion of hematopoietic cells. In addition, the feasibility of the process will be assessed based on the results of the release testing of the transduced cells prior to injection into the patient.
3. To measure the effect of HIV infection on the presence of HIV-resistant blood cells as measured by genetic marking for vector sequences before and after antiviral treatment interruption.

Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) 18-25, body weight should be ≥ 40kg;
* Meet the Diagnostic Criteria for AIDS and HIV Infection (WS293-2019), and be diagnosed as HIV seropositive;
* HIV infection combined with lymphoma, in partial remission or relapsed after initial complete remission, failed induction therapy, but responds to salvage therapy;
* Age-adjusted IPI 2-3 points;
* Meet the indications for autologous bone marrow transplantation after clinical evaluation;
* HIV viral load \<1000 copies/ml;
* Must have the ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Any HIV-related uncontrolled opportunistic infection, including fungal infection, sepsis, active tuberculosis, weightlessness, severe diarrhea, active opportunistic infections in the central nervous system or active hepatitis B, hepatitis C, and other viral infections such as CMV;
* Cardiac insufficiency (LVEF\<50%), renal insufficiency (creatinine\>2mg/dl), hepatic insufficiency (AST/ALT\>3 ULN and/or PT \<70% unrelated to lymphoma);
* HAART treatment failure (including at least one NRTI, one NNRTI and two PI) and/or CD4 count \< 50/cmm);
* Malignancy other than lymphoma, unless (1) in complete remission and more than 5 years from last treatment, or (2) cervical/anal squamous cell carcinoma in situ or (3) superficial basal cell and squamous cell cancers of the skin;
* Participation of other investigational agents (traditional Chinese medicine is not included) within 3 months；
* Any concurrent or past medical condition that, in the opinion of the Investigator, would exclude the subject from participation or any psychosocial conditions that would hinder study compliance or follow-up, at the discretion of the Investigator.

Primary outcomes:
measure: Overall survival
timeFrame: D0 post-infusion to completion of follow-up, an average of 2 year
measure: Engraftment time of 7shRNA modified CD34+ stem cells
timeFrame: within day +28 after gene therapy
Secondary outcomes:
measure: 7shRNA VCN
timeFrame: At week 2, months 1, 2, 3, 4, 5, 6, 7, 8, 9，10,12，15,18,21and 24 post-transplant
measure: Duration of interruption of HAART
timeFrame: Up to 24 months post-treatment
measure: Transplantation related mortality
timeFrame: Up to 24 months post-treatment
Other outcomes:
Locations:
city: Zhanjiang
country: China
facility: Affiliated hospital of Guangdong medical university
state: Guangdong
Study officials:
affiliation: Affiliated hospital of Guangdong medical university, Guangdong province, China
name: yuming Zhang, PhD
role: PRINCIPAL_INVESTIGATOR
References: